Continuing the third part of our ongoing CD47-SIRPα mini-series, we move on from the science and the competitive landscape to look at what CEOs in this niche have to say. There are many different approaches being evaluated at present, mostly in preclinical development, which makes it an intriguing area to potentially follow over time as new data emerges.
Not all of these molecules will be successful and the target is certainly not the easiest to attempt, although not as diffcult as MYC or RAS either!
When all is said an done, what do key players in this field think when they are developing compounds and how do they see the emerging challenges?
In this latest post, we have not one, but two CEOs, who were willing who share their candid thoughts and perceptions on the CD47-SIRPα space…